Header Logo

Connection

Jeffrey Kordower to alpha-Synuclein

Back to Details
This is a "connection" page, showing publications Jeffrey Kordower has written about alpha-Synuclein.
Jeffrey Kordower
Connection Strength
13.006
alpha-Synuclein
  1. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiol Dis. 2021 01; 148:105184.
    View in: PubMed
    Score: 0.633
  2. Intrastriatal alpha-synuclein fibrils in monkeys: spreading, imaging and neuropathological changes. Brain. 2019 11 01; 142(11):3565-3579.
    View in: PubMed
    Score: 0.588
  3. Spreading of alpha-synuclein - relevant or epiphenomenon? J Neurochem. 2019 09; 150(5):605-611.
    View in: PubMed
    Score: 0.575
  4. Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology. Neurobiol Dis. 2018 04; 112:106-118.
    View in: PubMed
    Score: 0.519
  5. Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017 12; 298(Pt B):225-235.
    View in: PubMed
    Score: 0.509
  6. Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathol Commun. 2017 06 16; 5(1):47.
    View in: PubMed
    Score: 0.499
  7. a-Synuclein nonhuman primate models of Parkinson's disease. J Neural Transm (Vienna). 2018 03; 125(3):385-400.
    View in: PubMed
    Score: 0.494
  8. Targeting a-Synuclein as a therapy for Parkinson's disease: The battle begins. Mov Disord. 2017 02; 32(2):203-207.
    View in: PubMed
    Score: 0.486
  9. How strong is the evidence that Parkinson's disease is a prion disorder? Curr Opin Neurol. 2016 Aug; 29(4):459-66.
    View in: PubMed
    Score: 0.469
  10. Parkinson's disease and prion disease: Straining the comparison. Mov Disord. 2015 Nov; 30(13):1727.
    View in: PubMed
    Score: 0.446
  11. Alpha-synuclein propagation: New insights from animal models. Mov Disord. 2016 Feb; 31(2):161-8.
    View in: PubMed
    Score: 0.441
  12. The native form of a-Synuclein: Monomer, tetramer, or a combination in equilibrium. Mov Disord. 2015 Dec; 30(14):1870.
    View in: PubMed
    Score: 0.438
  13. Peripheral alpha-synuclein and Parkinson's disease. Mov Disord. 2014 Jul; 29(8):963-6.
    View in: PubMed
    Score: 0.406
  14. The prion hypothesis of Parkinson's disease: this hot topic just got hotter. Mov Disord. 2014 Jul; 29(8):988.
    View in: PubMed
    Score: 0.404
  15. Abnormal alpha-synuclein reduces nigral voltage-dependent anion channel 1 in sporadic and experimental Parkinson's disease. Neurobiol Dis. 2014 Sep; 69:1-14.
    View in: PubMed
    Score: 0.402
  16. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord. 2014 Jul; 29(8):999-1009.
    View in: PubMed
    Score: 0.388
  17. Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain. 2012 Jul; 135(Pt 7):2058-73.
    View in: PubMed
    Score: 0.353
  18. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord. 2012 May; 27(6):716-9.
    View in: PubMed
    Score: 0.350
  19. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord. 2012 May; 27(6):709-15.
    View in: PubMed
    Score: 0.331
  20. Transfer of host-derived a synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis. 2011 Sep; 43(3):552-7.
    View in: PubMed
    Score: 0.327
  21. a-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease. Neurobiol Dis. 2011 Jan; 41(1):71-82.
    View in: PubMed
    Score: 0.312
  22. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009 Sep; 35(3):385-98.
    View in: PubMed
    Score: 0.286
  23. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis. 2007 Jan; 25(1):134-49.
    View in: PubMed
    Score: 0.238
  24. Proximity proteomics reveals unique and shared pathological features between multiple system atrophy and Parkinson's disease. Acta Neuropathol Commun. 2025 Mar 23; 13(1):65.
    View in: PubMed
    Score: 0.214
  25. Mixed pathology as a rule, not exception: Time to reconsider disease nosology. Handb Clin Neurol. 2023; 192:57-71.
    View in: PubMed
    Score: 0.183
  26. A historical review of multiple system atrophy with a critical appraisal of cellular and animal models. J Neural Transm (Vienna). 2021 10; 128(10):1507-1527.
    View in: PubMed
    Score: 0.168
  27. GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021 06; 153:105298.
    View in: PubMed
    Score: 0.161
  28. Anti-a-synuclein ASO delivered to monoamine neurons prevents a-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020 Sep; 59:102944.
    View in: PubMed
    Score: 0.155
  29. Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020 03 01; 143(3):960-975.
    View in: PubMed
    Score: 0.150
  30. Temporal evolution of microglia and a-synuclein accumulation following foetal grafting in Parkinson's disease. Brain. 2019 06 01; 142(6):1690-1700.
    View in: PubMed
    Score: 0.143
  31. Loss of One Engrailed1 Allele Enhances Induced a-Synucleinopathy. J Parkinsons Dis. 2019; 9(2):315-326.
    View in: PubMed
    Score: 0.139
  32. Detecting Alpha Synuclein Seeding Activity in Formaldehyde-Fixed MSA Patient Tissue by PMCA. Mol Neurobiol. 2018 Nov; 55(11):8728-8737.
    View in: PubMed
    Score: 0.132
  33. Do subjects with minimal motor features have prodromal Parkinson disease? Ann Neurol. 2018 03; 83(3):562-574.
    View in: PubMed
    Score: 0.131
  34. Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient. Ann Neurol. 2017 Jan; 81(1):46-57.
    View in: PubMed
    Score: 0.121
  35. The Search for a Peripheral Biopsy Indicator of a-Synuclein Pathology for Parkinson Disease. J Neuropathol Exp Neurol. 2017 01 01; 76(1):2-15.
    View in: PubMed
    Score: 0.121
  36. Multicenter Assessment of Immunohistochemical Methods for Pathological Alpha-Synuclein in Sigmoid Colon of Autopsied Parkinson's Disease and Control Subjects. J Parkinsons Dis. 2016 10 19; 6(4):761-770.
    View in: PubMed
    Score: 0.119
  37. Evaluation of alpha-synuclein immunohistochemical methods for the detection of Lewy-type synucleinopathy in gastrointestinal biopsies. Acta Neuropathol Commun. 2016 Apr 04; 4:35.
    View in: PubMed
    Score: 0.115
  38. Preface. Mov Disord. 2016 Feb; 31(2):151.
    View in: PubMed
    Score: 0.113
  39. Alterations in Activity-Dependent Neuroprotective Protein in Sporadic and Experimental Parkinson's Disease. J Parkinsons Dis. 2016; 6(1):77-97.
    View in: PubMed
    Score: 0.113
  40. The prion hypothesis of Parkinson's disease. Curr Neurol Neurosci Rep. 2015 May; 15(5):28.
    View in: PubMed
    Score: 0.108
  41. Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with a-synucleinopathies. Neurobiol Dis. 2015 Jun; 78:162-71.
    View in: PubMed
    Score: 0.107
  42. Can intrabodies serve as neuroprotective therapies for Parkinson's disease? Beginning thoughts. J Parkinsons Dis. 2013; 3(4):581-91.
    View in: PubMed
    Score: 0.092
  43. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One. 2011; 6(12):e28032.
    View in: PubMed
    Score: 0.085
  44. Lewy body pathology in fetal grafts. Ann N Y Acad Sci. 2010 Jan; 1184:55-67.
    View in: PubMed
    Score: 0.074
  45. Decreased alpha-synuclein expression in the aging mouse substantia nigra. Exp Neurol. 2009 Dec; 220(2):359-65.
    View in: PubMed
    Score: 0.073
  46. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008 May; 14(5):504-6.
    View in: PubMed
    Score: 0.066
  47. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol. 2006 Aug; 60(2):264-8.
    View in: PubMed
    Score: 0.059
  48. Nurr1 in Parkinson's disease and related disorders. J Comp Neurol. 2006 Jan 20; 494(3):495-514.
    View in: PubMed
    Score: 0.057
  49. Inflammation in Experimental Models of a-Synucleinopathies. Mov Disord. 2021 01; 36(1):37-49.
    View in: PubMed
    Score: 0.039
  50. Analysis of age-related changes in psychosine metabolism in the human brain. PLoS One. 2018; 13(2):e0193438.
    View in: PubMed
    Score: 0.033
  51. Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. Sci Transl Med. 2016 12 07; 8(368):368ra174.
    View in: PubMed
    Score: 0.030
  52. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci. 2003 Sep; 4(9):727-38.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.